Atypical anti-psychotics in adult bipolar disorder: Current evidence and updates in the nice guidelines

Psychiatria Danubina

Volumn 26, Issue , 2014, Pages 322-329

  Poo, Stephanie Xiu Wern ^a,b   Agius, Mark ^c,d,e,f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NEWNHAM COLLEGE   (United Kingdom)

^c South Essex University Partnership Foundation Trust ^*  (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e CLARE COLLEGE   (United Kingdom)

^f BEDFORD HOSPITAL   (United Kingdom)

Author keywords

Adult; Aripiprazole; Asenapine; Atypical antipsychotics; Bipolar disorder; Clozapine; Fluoxetine; Lurasidone; NICE guidelines; Olanzapine; Quetiapine; Risperidone; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; LURASIDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ADULT; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL PRACTICE; COCHRANE LIBRARY; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EMBASE; EVIDENCE BASED MEDICINE; HUMAN; HYPOMANIA; MAINTENANCE THERAPY; MANIA; MEDLINE; MENTAL PATIENT; MONOTHERAPY; OFF LABEL DRUG USE; PRACTICE GUIDELINE; PSYCINFO; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID CYCLING BIPOLAR DISORDER; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; THERAPY;

EID: 84918800669     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.) 2013. Arlington, VA: American Psychiatric Publishing. http://www.dsm5.org.
2. Amsterdam J & Shults J: Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction. Journal of Affective Disorders 2005; 87:121-130.
3. Anderson IM, Haddad PM, Scott J: "Bipolar disorder." BMJ (Clinical research ed.) 2012; 345:e8508.
4. Arnold W, Mech: High-Dose Ziprasidone Monotherapy in Bipolar I Disorder Patients With Depressed or Mixed Episodes. Journal of Clinical Psychopharmacology 2008; 28:240-1.
5. Azorin JM, Sapin C & Weiller E: Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: Results from post hoc analyses. Journal of Affective Disorders 2013; 145:62-69.
6. Baker RW, Goldberg JF, Tohen M, Miltona DR, Stauffer VL & Schuh LM: The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania. Bipolar Disorders 2002; 4:43-49.
7. Baker R, Milton R, Stauffer L, Gelenberg A & Tohen M: Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania. Journal of Affective Disorders 2003; 73:147-153.
8. Baldassano C, Ballas C, Datto S, Kim D, Littman L, O'Reardon J and Rynn M: Ziprasidone-associated mania: a case series and review of the mechanism. Bipolar Disorders 2003; 5:72-75.
9. Bartolommei N, Casamassima F, Pensabene L, Luchini F, Benvenuti A, Di Paolo A, Cosentino L, et al.: Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine. ISRN Psychiatry 2014; 904829.
10. Brown R, Taylor MJ, Geddes J: Aripiprazole alone or in combination for acute mania. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD005000.
11. Brown E, Dunner L, McElroy L, Keck Jr E, Adams H, Degenhardt E, Tohen M, et al.: Olanzapine/fluoxetine combination vs. Lamotrigine in the 6-month treatment of bipolar I depression. International Journal of Neuropsychopharmacology 2009; 12:773-782.
12. Calabrese JR, Loebel A, Cucchiaro J, et al.: Lurasidone adjunctive to lithium or valproate for the treatment of bipolar I depression: results of the 6-week, double-blind, placebo-controlled PREVAIL-1study Neuropsychopharmacology 2012; 38(S1):32.
13. Calabrese R, Keck Jr E, Macfadden W, Minkwitz M, Ketter A, Weisler H, Cutler J, et al.: A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression. The American Journal of Psychiatry 2005; 162:1351-1360.
14. Carlson X, Ketter A, Sun W, Timko K, McQuade D, Sanchez R, Vester-Blokland E, et al.: Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): A randomized, multicenter, double-blind study (CN138-392). Bipolar Disorders 2012; 14:41-53.
15. Cipriani A, Barbui C, Salanti G, et al.: Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011; 378:1306-1315.
16. Citrome L, Ketter TA, Cucchiaro J & Loebel A: Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 2013, 155:20-27.
17. Corya A, Perlis H, Keck Jr E, Lin Y, Case G, Williamson J & Tohen FA: 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression. Journal of Clinical Psychiatry 2006; 67:798-806.
18. De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, Sienaert P, et al.: Second generation antipsychotics in the treatment of bipolar depression: A systematic review and meta-analysis. Journal of Psychopharmacology 2012; 26:603-617.
19. Ghaemi SN, Hsu DJ, Soldani F and Goodwin FK: Antidepressants in bipolar disorder: the case for caution. Bipolar Disorders 2003; 5:421-433.
20. Grohol J: Atypical Antipsychotics for Bipolar Disorder. Psych Central 2008; 0001421.
21. Guy W, editor: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, 1976.
22. Hirschfeld RMA, Keck PE, Kramer M, Karcher K, Canuso C, Eerdekens M & Grossman F: Rapid antimanic effect of risperidone monotherapy: A 3-week multicenter, doubleblind, placebo-controlled trial. American Journal of Psychiatry 2004; 161:1057-1065.
23. Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press 〈http://www.bnf.org〉 [Accessed on 29th September 2014].
24. Kanba S, Kawasaki H, Ishigooka J, Sakamoto K, Kinoshita T, Kuroki T: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study) World J Biol Psychiatry, 2012 Apr 30; Epub.
25. Kendall Tim, Morriss Richard, Mayo-Wilson Evan, Marcus Elena 2014. Assessment and management of bipolar disorder: summary of updated NICE guidance [BMJ 2014;349:g5673].
26. Loebel A, Cucchiaro J, Silva R, et al.: Lurasidone monotherapy for the treatment of bipolar depression: results of the 6-week, double-blind, placebo-controlled PREVAIL-2 study Neuropsychopharmacology 2012; 38S422-S423.S423.
27. Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W & Sanchez R: Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: A multicenter, double-blind, randomized study. Bipolar Disorders 2011; 13;133-144.
28. McElroy L, Weisler H, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, et al.: A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Journal of Clinical Psychiatry 2010; 71:163-174.
29. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA and Panagides JA: 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disorders 2009; 11:673-686.
30. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA & Panagides J: Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebocontrolled trial. Journal of Affective Disorders 2009; 122:27-38.
31. McIntyre RS, Tohen M, Berk M, Zhao, J & Weiller E: DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. Journal of affective disorders 2013; 150:378-83.
32. McIntyre S, Cohen M, Zhao J, Alphs L, Macek, A & Panagides J: Asenapine versus olanzapine in acute mania: A double-blind extension study. Bipolar Disorders 2009; 11:815-826.
33. McIntyre S, Konarski Z, Jones M & Paulsson B: Quetiapine in the treatment of acute bipolar mania: Efficacy across a broad range of symptoms. Journal of Affective Disorders 2007; 100 (Suppl 1):S5-S14.
34. Montgomery SA and Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-89.
35. National Institute for Health and Care Excellence: Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. [CG38]. London: National Institute for Health and Care Excellence, 2006.
36. National Institute for Health and Care Excellence: Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. [CG185]. London: National Institute for Health and Care Excellence, 2014.
37. Niufan G, Tohen M, Qiuqing A, Fude Y, Pope E, McElroy H, Ming L, et al.: Olanzapine versus lithium in the acute treatment of bipolar mania: A double-blind, randomized, controlled trial. Journal of Affective Disorders 2008; 105:101-108.
38. Quante A, Zeugmann S, Luborzewski A, Schommer N, Langosch J, Born C, Anghelescu I, et al.: Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: A randomized placebo-controlled pilot study. Human Psychopharmacology: Clinical and Experimental 2010; 25:126-132.
39. Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, Lackner E, et al.: Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers. Neuropsychopharmacology 2007; 33:1633-1641.
40. Sachs S, Grossman F, Ghaemi Nassir S, Okamoto A & Bowden L: Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safety. The American Journal of Psychiatry 2002; 159:1146-1154.
41. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C & Darko D: Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. Journal of Affective Disorders 2010; 121:106-115.
42. Suppes T, Webb A, Paul B, Carmody T, Kraemer H & Rush John A: Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. The American Journal of Psychiatry 1999; 156:1164-1169.
43. Szegedi A, Zhao J, Van Arjen W, Nations R, Mackle M & Panagides J: Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: A post hoc analysis of two 3-week clinical trials. BMC Psychiatry 2011; 11:101.
44. Thase E, Jonas A, Khan A, Bowden L, Wu X, McQuade D, Carson H, et al.: Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology 2008; 28:13-20.
45. Thase E, Macfadden W, Weisler H, Chang W, Paulsson B, Khan, A, Calabrese R, et al.: Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression: A Doubleblind, Placebo-controlled Study (The BOLDER II Study). Journal of Clinical Psychopharmacology 2006; 26:600-609.
46. Tohen M, McDonnell DP, Case M, et al.: Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 2012; 201:376-382.
47. Tohen M, Vieta E, Calabrese J, et al.: Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression. Arch Gen Psychiatry 2003; 60:1079-1088.
48. Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ph D, Ketter TA, et al.; Olanzapine versus Divalproex in the Treatment of Acute Mania, American Journal of Psychiatry 2002; 159:1011-1017.
49. Tohen M, Sanger M, McElroy L, Tollefson D, Chengappa Roy KN, Daniel G, Petty F, et al.: Olanzapine versus placebo in the treatment of acute mania. The American Journal of Psychiatry 1999;156:702-709.
50. Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J: Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol 2010; 24:547-558.
51. Vieta E, Montgomery S, Sulaiman Hatim A, Cordoba R, Huberlant B, Martinez L & Schreiner A: A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. European Neuropsychopharmacology 2012; 22:825-835.
52. Vieta E, Owen R, Baudelet C, McQuade D, Sanchez R & Marcus N: Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: A 46-week, open-label extension following a 6-week double-blind study. Current Medical Research and Opinion 2010; 26:1485-1496.
53. Vieta E, Suppes T, Ekholm B, Udd M, & Gustafsson U: Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. Journal of Affective Disorders 2012; 142:36-44.
54. Wahlbeck K, Cheine M, Essali A, Adams C: Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156:990-999.
55. WHO: The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines, 1992.
56. Woo YS, Wang HR, Bahk WM: Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat 2013; 9:1521-1529.
57. Yatham LN, Fountoulakis KN, Rahman Z, Ammerman D, Fyans P, Marler SV, Baker RA, et al.: Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. Journal of Affective Disorders 2014; 147:365-372.
58. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429-435.
59. Young AH, Calabrese JR, Gustafsson U, Berk M, McElroy SL, Thase ME, Suppes T, et al.: Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. International Journal of Bipolar Disorders 2013; 1:10.
60. Young H, McElroy L, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, et al.: A double-blind, placebocontrolled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). Journal of Clinical Psychiatry 2010; 71:150-162.
61. Young H, Oren A, Lowy A, McQuade D, Marcus N, Carson H, Spiller H, et al.: Aripiprazole monotherapy in acute mania: 12-week, randomised placebo- and haloperidol-controlled study. The British Journal of Psychiatry 2009; 194:40-48.